This Special Communication discusses the Food and Drug Administration's (FDA's) proposed rule that would limit N-nitrosonornicotine (NNN) levels in smokeless tobacco products. It argues that finalising and implementing this first 'product standard' would mark a significant step forward in the FDA's efforts to reduce tobacco-related harms.
|Original language||English (US)|
|Number of pages||3|
|State||Published - May 1 2018|
- Non-cigarette tobacco products
- harm reduction
- public policy